121 related articles for article (PubMed ID: 12887410)
1. Binding characteristics of [3H]14-methoxymetopon, a high affinity mu-opioid receptor agonist.
Spetea M; Tóth F; Schütz J; Otvös F; Tóth G; Benyhe S; Borsodi A; Schmidhammer H
Eur J Neurosci; 2003 Jul; 18(2):290-5. PubMed ID: 12887410
[TBL] [Abstract][Full Text] [Related]
2. Separation of binding affinity and intrinsic activity of the potent mu-opioid 14-methoxymetopon.
Mahurter L; Garceau C; Marino J; Schmidhammer H; Tóth G; Pasternak GW
J Pharmacol Exp Ther; 2006 Oct; 319(1):247-53. PubMed ID: 16801454
[TBL] [Abstract][Full Text] [Related]
3. Mu-opioid receptor specific antagonist cyprodime: characterization by in vitro radioligand and [35S]GTPgammaS binding assays.
Márki A; Monory K; Otvös F; Tóth G; Krassnig R; Schmidhammer H; Traynor JR; Roques BP; Maldonado R; Borsodi A
Eur J Pharmacol; 1999 Oct; 383(2):209-14. PubMed ID: 10585536
[TBL] [Abstract][Full Text] [Related]
4. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
Zhao GM; Qian X; Schiller PW; Szeto HH
J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
[TBL] [Abstract][Full Text] [Related]
5. Studies of micro-, kappa-, and delta-opioid receptor density and G protein activation in the cortex and thalamus of monkeys.
Ko MC; Lee H; Harrison C; Clark MJ; Song HF; Naughton NN; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2003 Jul; 306(1):179-86. PubMed ID: 12676881
[TBL] [Abstract][Full Text] [Related]
6. Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor.
Emmerson PJ; Clark MJ; Mansour A; Akil H; Woods JH; Medzihradsky F
J Pharmacol Exp Ther; 1996 Sep; 278(3):1121-7. PubMed ID: 8819494
[TBL] [Abstract][Full Text] [Related]
7. Novel approach to demonstrate high efficacy of mu opioids in the rat vas deferens: a simple model of predictive value.
Riba P; Friedmann T; Király KP; Al-Khrasani M; Sobor M; Asim MF; Spetea M; Schmidhammer H; Furst S
Brain Res Bull; 2010 Jan; 81(1):178-84. PubMed ID: 19800397
[TBL] [Abstract][Full Text] [Related]
8. In vitro binding and signaling profile of the novel mu opioid receptor agonist endomorphin 2 in rat brain membranes.
Spetea M; Monory K; Tömböly C; Tóth G; Tzavara E; Benyhe S; Hanoune J; Borsodi A
Biochem Biophys Res Commun; 1998 Sep; 250(3):720-5. PubMed ID: 9784412
[TBL] [Abstract][Full Text] [Related]
9. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
[TBL] [Abstract][Full Text] [Related]
10. The steroid 17alpha-acetoxy-6-dimethylaminomethyl-21-fluoro-3-ethoxy-pregna-3, 5-dien-20-one (SC17599) is a selective mu-opioid agonist: implications for the mu-opioid pharmacophore.
McFadyen IJ; Houshyar H; Liu-Chen LY; Woods JH; Traynor JR
Mol Pharmacol; 2000 Oct; 58(4):669-76. PubMed ID: 10999935
[TBL] [Abstract][Full Text] [Related]
11. Characterisation and visualisation of [3H]dermorphin binding to mu opioid receptors in the rat brain. Combined high selectivity and affinity in a natural peptide agonist for the morphine (mu) receptor.
Amiche M; Sagan S; Mor A; Pelaprat D; Rostene W; Delfour A; Nicolas P
Eur J Biochem; 1990 May; 189(3):625-35. PubMed ID: 2161761
[TBL] [Abstract][Full Text] [Related]
12. Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.
Traynor JR; Nahorski SR
Mol Pharmacol; 1995 Apr; 47(4):848-54. PubMed ID: 7723747
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the binding of [3H][Dmt1]H-Dmt-D-Arg-Phe-Lys-NH2, a highly potent opioid peptide.
Neilan CL; Janvey AJ; Bolan E; Berezowska I; Nguyen TM; Schiller PW; Pasternak GW
J Pharmacol Exp Ther; 2003 Aug; 306(2):430-6. PubMed ID: 12663687
[TBL] [Abstract][Full Text] [Related]
14. 3-Deoxyclocinnamox: the first high-affinity, nonpeptide mu-opioid antagonist lacking a phenolic hydroxyl group.
Derrick I; Neilan CL; Andes J; Husbands SM; Woods JH; Traynor JR; Lewis JW
J Med Chem; 2000 Aug; 43(17):3348-50. PubMed ID: 10966754
[TBL] [Abstract][Full Text] [Related]
15. Differential involvement of mu(1)-opioid receptors in endomorphin- and beta-endorphin-induced G-protein activation in the mouse pons/medulla.
Mizoguchi H; Narita M; Wu H; Narita M; Suzuki T; Nagase H; Tseng LF
Neuroscience; 2000; 100(4):835-9. PubMed ID: 11036217
[TBL] [Abstract][Full Text] [Related]
16. Tolerance to mu-opioid agonists in human neuroblastoma SH-SY5Y cells as determined by changes in guanosine-5'-O-(3-[35S]-thio)triphosphate binding.
Elliott J; Guo L; Traynor JR
Br J Pharmacol; 1997 Aug; 121(7):1422-8. PubMed ID: 9257923
[TBL] [Abstract][Full Text] [Related]
17. Signal transduction efficacy of the highly potent mu opioid agonist 14-methoxymetopon.
Zernig G; Saria A; Krassnig R; Schmidhammer H
Life Sci; 2000 Mar; 66(19):1871-7. PubMed ID: 10809184
[TBL] [Abstract][Full Text] [Related]
18. Receptor binding and G-protein activation by new Met5-enkephalin-Arg6-Phe7 derived peptides.
Bozó B; Farkas J; Tóth G; Wollemann M; Szucs M; Benyhe S
Life Sci; 2000 Feb; 66(13):1241-51. PubMed ID: 10737419
[TBL] [Abstract][Full Text] [Related]
19. SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors.
Xu H; Lu YF; Rice KC; Ananthan S; Rothman RB
Brain Res Bull; 2001 Jul; 55(4):507-11. PubMed ID: 11543951
[TBL] [Abstract][Full Text] [Related]
20. Selectivity of mu-opioid receptor determined by interfacial residues near third extracellular loop.
Bonner G; Meng F; Akil H
Eur J Pharmacol; 2000 Sep; 403(1-2):37-44. PubMed ID: 10969141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
